Close Menu

SAN FRANCISCO - On the second day of the 38th annual JP Morgan Healthcare Conference, GlaxoSmithKline discussed its forthcoming plans for niraparib (Zejula), and Amgen noted that given the interest in its KRAS G12C inhibitor that a lung cancer study had quickly finished enrollment at the end of last year. Below are brief reports on the presentations covered by our team at the conference and in our offices in New York.


GlaxoSmithKline

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.